Understanding genetic factors in autoimmune diseases in Peru
Official title: Deciphering the Genetic Architecture of Autoimmune Diseases
Run by National Institutes of Health Clinical Center (CC) · NCT06948110 · Data updated 2026-11-12
This study is looking to see how genetic differences affect autoimmune diseases in people from Peru to better understand their health needs.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 115 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 2 sites (Bethesda, Maryland and 1 other locations) |
| Status | Recruiting |
| Started | November 15, 2026 |
| Main results expected | April 22, 2030 |
| Study ends | April 22, 2030 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT06948110 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 18 and older diagnosed with autoimmune diseases such as systemic lupus erythematosus, Sjogren's disease, and rheumatoid arthritis.
✕Probably not a fit
Patients with chronic viral diseases like HIV or hepatitis C will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the genetic factors contributing to autoimmune diseases, particularly focusing on individuals native to Peru. Researchers will analyze how genetic variations influence the risk and manifestation of conditions like systemic lupus erythematosus among this population. Participants will undergo two clinic visits spaced two weeks apart, where their genetic information and health data will be collected. The study seeks to address health disparities and improve understanding of autoimmune diseases in non-European populations.
Why it matters
Potential benefit: If successful, this study could lead to better diagnosis and treatment strategies for autoimmune diseases in diverse populations.
How similar studies have gone: While there is limited research specifically targeting the genetic architecture of autoimmune diseases in indigenous populations, studies in other regions have shown the importance of genetic diversity in understanding these conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: Any person who meets the criteria for inclusion in the study will be considered and must have the patient's signed informed consent for participation. Autoimmune Disease Diagnosis: Cases: * Patients diagnosed with SLE, Sjogren's disease, scleroderma, rheumatoid arthritis, seronegative spondyloarthropathies, and systemic vasculitis, as defined by the American College of Rheumatology classification criteria. * Over 18 years old Controls: * Family members of identified cases, and unrelated individuals. The controls would be from the same community as the patients and families studied, and of the same age and gender. Screening for autoimmune diseases and allergic diseases will be performed. * Over 18 years old EXCLUSION CRITERIA: -People diagnosed with a chronic viral disease: HIV, hepatitis C or HTLV-1.
Where it's running
-
Amazon Rainforest
Lima, Peru Recruiting -
National Human Genome Research Institute (NHGRI)
Bethesda, Maryland, United States Completed
Study contacts
- Principal investigator: Cristina M Lanata, M.D. — National Human Genome Research Institute (NHGRI)
- Study coordinator: Cristina M Lanata, M.D.
- Email: cristina.lanata@nih.gov
- Phone: (301) 451-2302
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ETHY-001 safety and activity in Thyroid Eye Disease (TED)
This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
Music-4-MS: A 12-week music-based program to support thinking skills in people with MS
A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.
-
ATG-201 in adults with autoimmune diseases
This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.
-
AMX0035 in adults with Type 1 Diabetes
This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.
-
CD19/BCMA UCART for B cell–related autoimmune diseases
This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.